Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Neuropsychopharmacology · 2002-04-01 · Randomised trial
Abstract
This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES > or =8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antipsychotics · Other benzodiazepines & Z-drugs · Older adults · Sedatives & anxiolytics
Related articles
- Agitation management strategies for older adults in the emergency department or with emergency medical services: A scoping review. (Am J Emerg Med, 2025)
- Prehospital Sedation and Physical Restraint of Older Adults Presenting With Behavioral Health Emergencies: A Nationwide Cross-Sectional Study. (J Am Geriatr Soc, 2026)
- Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review. (Front Psychiatry, 2021)
- Randomized Double-blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department. (Acad Emerg Med, 2021)
- Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study. (Am J Emerg Med, 2021)
- Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. (J Formos Med Assoc, 2015)